Journey Company Profile
What is the competitive landscape for JOURNEY
JOURNEY has nine approved drugs.
There are thirty-one US patents protecting JOURNEY drugs.
Summary for Journey
| US Patents: | 31 |
| Tradenames: | 7 |
| Ingredients: | 4 |
| NDAs: | 9 |
| Patent Litigation for Journey: | See patent lawsuits for Journey |
Drugs and US Patents for Journey
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Journey | XIMINO | minocycline hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 201922-003 | Jul 11, 2012 | DISCN | No | No | 7,541,347 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Journey | XIMINO | minocycline hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 201922-004 | Jul 11, 2012 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| Journey | EMROSI | minocycline hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 219015-001 | Nov 1, 2024 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Journey
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Journey | XIMINO | minocycline hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 201922-005 | Jul 11, 2012 | 7,790,705 | ⤷ Start Trial |
| Journey | XIMINO | minocycline hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 201922-001 | Jul 11, 2012 | 5,908,838 | ⤷ Start Trial |
| Journey | XIMINO | minocycline hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 201922-001 | Jul 11, 2012 | 8,268,804 | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for Journey Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| New Zealand | 710740 | ⤷ Start Trial |
| United Kingdom | 2474930 | ⤷ Start Trial |
| Israel | 218866 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Journey Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2515855 | 201740046 | Slovenia | ⤷ Start Trial | PRODUCT NAME: COMBINATION OF GLYCOPYRRONIUM BROMIDE, FORMOTEROL OR ITS SALT AND BECLOMETASONE DIPROPIONATE; NATIONAL AUTHORISATION NUMBER: EU/1/17/1208/001-005; DATE OF NATIONAL AUTHORISATION: 20170717; AUTHORITY FOR NATIONAL AUTHORISATION: EU |
| 2515855 | 1890005-0 | Sweden | ⤷ Start Trial | PRODUCT NAME: A COMBINATION OF GLYCOPYRRONIUM BROMIDE, FORMOTEROL OR A SALT THEREOF AND BECLOMETASONE DIPROPIONATE.; FIRST MARKETING AUTHORIZATION NUMBER SE: EG EU/1/17/1208, 2017-07-19; DEN 2025-05-19 MEDDELADE PRV BESLUT OM RAETTAD SKYDDSTID FOER FOELJANDE TILLAEGGSSKYDD: 1590005-3,1890005-0 |
| 2435025 | 300995 | Netherlands | ⤷ Start Trial | PRODUCT NAME: COMBINATIE VAN GLYCOPYRRONIUM, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT OF ESTER, IN HET BIJZONDER GLYCOPYRRONIUYM BROMIDE, EN FORMOTEROL, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT OF ESTER, IN HET BIJZONDER FORMOTEROL FUMARAAT DIHYDRAAT; REGISTRATION NO/DATE: EU/ 1/18/1339 20181220 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
